Henry Schein (NASDAQ:HSIC – Free Report) had its price objective lifted by Morgan Stanley from $64.00 to $68.00 in a research report sent to investors on Tuesday,Benzinga reports. Morgan Stanley currently has an underweight rating on the stock.
Other research analysts have also recently issued research reports about the stock. BTIG Research increased their target price on shares of Henry Schein from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, August 19th. Leerink Partners set a $92.00 target price on shares of Henry Schein and gave the company a “market perform” rating in a research report on Wednesday, October 14th. Weiss Ratings upgraded shares of Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, August 21st. Piper Sandler boosted their price target on shares of Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, UBS Group increased their price objective on shares of Henry Schein from $94.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 4th. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Henry Schein presently has a consensus rating of “Moderate Buy” and an average price target of $93.86.
Read Our Latest Analysis on Henry Schein
Henry Schein Trading Down 1.0%
NASDAQ HSIC opened at $84.80 on Tuesday. Henry Schein has a 52 week low of $68.70 and a 52 week high of $92.18. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.76 and a current ratio of 1.33. The stock’s 50 day moving average price is $85.60 and its two-hundred day moving average price is $81.73. The stock has a market capitalization of $9.37 billion, a price-to-earnings ratio of 23.23, a PEG ratio of 1.60 and a beta of 0.87.
Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.20. Henry Schein had a net margin of 3.07% and a return on equity of 16.39%. The company had revenue of $3.47 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same period last year, the business earned $1.38 EPS. The business’s quarterly revenue was up 4.0% on a year-over-year basis. As a group, analysts anticipate that Henry Schein will post 5.45 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Parallel Advisors LLC raised its holdings in shares of Henry Schein by 12.7% in the 1st quarter. Parallel Advisors LLC now owns 1,314 shares of the company’s stock valued at $97,000 after purchasing an additional 148 shares during the period. Mufg Securities Americas Inc. grew its holdings in Henry Schein by 5.3% during the second quarter. Mufg Securities Americas Inc. now owns 2,917 shares of the company’s stock worth $244,000 after purchasing an additional 148 shares during the period. New Mexico Educational Retirement Board grew its holdings in Henry Schein by 4.2% during the second quarter. New Mexico Educational Retirement Board now owns 4,950 shares of the company’s stock worth $413,000 after purchasing an additional 200 shares during the period. Czech National Bank increased its position in Henry Schein by 1.1% during the second quarter. Czech National Bank now owns 27,561 shares of the company’s stock worth $2,302,000 after buying an additional 308 shares during the last quarter. Finally, Sanctuary Advisors LLC increased its position in Henry Schein by 7.7% during the first quarter. Sanctuary Advisors LLC now owns 5,231 shares of the company’s stock worth $386,000 after buying an additional 375 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.
Henry Schein Company Profile
Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.
Further Reading
- Five stocks we like better than Henry Schein
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
